1-2 of 2
S. Durrant
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML

Andrew W. Roberts, MBBS, PhD, Simon He, MBBS, Kenneth F Bradstock, MB, PhD, FRACP, FRCPA, Mark S Hertzberg, MBBS, FRACP, FRCP, PhD, Simon T S Durrant, MRCS, MBBS, MRCP, FRCP, David Ritchie, MBChB, FRACP, FRCPA, PhD, Ian D. Lewis, MBBS, PhD, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Andrew J McLachlan, PhD, Trina M Yeadon, PhD, Samantha J Busfield, PhD, Megan J Barnden, PhD, Roslyn Davis, BSc(Hons), Sarah Hosback, PhD, Danijela Mirosa, PhD, Mark Biondo, PhD, Simone Bamford, MBBS, FRACGP, Mark DeWitte, VMD, Russell Basser, MBBS, MD, FRACP
Journal: Blood
Blood (2008) 112 (11): 2956.
https://doi.org/10.1182/blood.V112.11.2956.2956
Published: 2008
Journal Articles

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

Susan Branford, Z. Rudzki, A. Grigg, J. F. Seymour, K. Taylor, P. Browett, A. Schwarer, K. Bradstock, C. Arthur, S. Durrant, D. Ma, D. Joske, K. Lynch, T. Hughes
Journal: Blood
Blood (2004) 104 (11): 274.
https://doi.org/10.1182/blood.V104.11.274.274
Published: 2004